Raltegravir chewable tablet

DRUG2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Merck Sharp & Dohme LLC

Conditions

HIV InfectionHIV Infections

Phase 1

Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents

CompletedNCT00485264

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2007-09-17End: 2017-05-18Updated: 2021-11-02

Phase 2

A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248)

CompletedNCT01717287

Merck Sharp & Dohme LLCHIV Infection

Start: 2012-11-16End: 2013-12-11Updated: 2018-08-21

Related Papers

Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial.

2018-12-017 citations

Pharmacokinetics, Safety, and 48-Week Efficacy of Oral Raltegravir in HIV-1-Infected Children Aged 2 Through 18 Years

Clinical Infectious Diseases2013-10-2159 citations